»ý¾î ½ÃÄö½º ½ÃÀå ºÐ¼®°ú ¿¹Ãø(-2033³â) : À¯Çüº°, Á¦Ç°º°, ¼­ºñ½ºº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, ÄÄÆ÷³ÍÆ®º°, ´Ü°èº°
Sanger Sequencing Market Analysis and Forecast to 2033: Type, Product, Services, Technology, Application, End User, Component, Stage
»óǰÄÚµå : 1632944
¸®¼­Ä¡»ç : Global Insight Services LLC
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 355 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,872,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 8,319,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,766,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ »ý¾î ½ÃÄö½º ½ÃÀåÀº CAGR 5.2%¸¦ ¹Ý¿µÇϰí, 2023³â 35¾ï ´Þ·¯¿¡¼­ 2033³â¿¡´Â 59¾ï ´Þ·¯·Î È®´ëÇÒ Àü¸ÁÀÔ´Ï´Ù.

½Ì°Å ½ÃÄö½Ì ½ÃÀåÀº ½Ì°Å ½ÃÄö½Ì ±â¼úÀÇ °³¹ß, »ý»ê, À¯ÅëÀ» Àü¹®À¸·Î ÇÏ´Â »ê¾÷À» Æ÷°ýÇÕ´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â À¯ÀüüÇÐ, Áø´Ü, ¿¬±¸¿ë DNA ½ÃÄö½Ì¿¡ »ç¿ëµÇ´Â ½Ã¾à, Àåºñ, ¼­ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. ¸ÂÃãÇü ÀÇ·á, À¯ÀüÀÚ °Ë»ç, ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ ¹ßÀüÀ» Áö¿øÇϸç, DNA ºÐ¼®ÀÇ ³ôÀº Á¤È®µµ¿Í ½Å·Ú¼º¿¡ ÁßÁ¡À» µÎ°í Çмú, ÀÓ»ó, Á¦¾à ºÐ¾ß¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.

½Ì°Å ½ÃÄö½Ì ½ÃÀåÀº À¯ÀüüÇÐ ¹× ¸ÂÃãÇü ÀÇ·áÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¼Ò¸ðǰ ºÐ¾ß, ƯÈ÷ ½Ã¾à ¹× ŰƮ´Â ½ÃÄö½Ì °úÁ¤¿¡¼­ ¹Ýº¹ÀûÀ¸·Î »ç¿ëµÇ¹Ç·Î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ½ÃÄö½Ì ¼­ºñ½º´Â ¿¬±¸±â°ü°ú Á¦¾à»çÀÇ ½ÃÄö½Ì ÇÁ·ÎÁ§Æ® ¾Æ¿ô¼Ò½Ì Áõ°¡¿¡ ÈûÀÔ¾î µÎ ¹øÂ°·Î ³ôÀº ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ½ÃÀåÀ» ¼±µµÇϰí Àִµ¥, ÀÌ´Â Àß ±¸ÃàµÈ ÇコÄɾî ÀÎÇÁ¶ó¿Í ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ¿¡ ±âÀÎÇÕ´Ï´Ù. À¯·´Àº Á¤ºÎÀÇ Áö¿ø Á¤Ã¥°ú Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ÁýÁßÀûÀÎ ³ë·ÂÀ¸·Î ÀÎÇØ µÎ ¹øÂ°·Î À¯¸®ÇÑ Áö¿ªÀÔ´Ï´Ù. ±¹°¡º°·Î´Â ¹Ì±¹ÀÌ ±â¼ú Çõ½Å°ú ÁÖ¿ä ±â¾÷ ÁýÁßÀ¸·Î ÀÎÇØ 1À§¸¦ Â÷ÁöÇß½À´Ï´Ù. µ¶ÀÏÀº źźÇÑ »ý¸í°øÇÐ ºÎ¹®°ú °øµ¿ ¿¬±¸ ±¸»ó¿¡ ÈûÀÔ¾î µÎ ¹øÂ°·Î ³ôÀº ¼º°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ªÇаü°è´Â ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå°ú Çõ½ÅÀÇ ÀáÀç·ÂÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

2023³â ½Ì°Å ½ÃÄö½Ì ½ÃÀåÀº 3¾ï °ÇÀ¸·Î Ãß»êµÇ¸ç, 2033³â¿¡´Â 5¾ï °Ç¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇöÀç Áø´Ü ºÐ¾ß°¡ 45%À¸·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ¿¬±¸¿ëÀÌ 35%, ³ó¾÷ ºÐ¾ß°¡ 20%À¸·Î ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. Áø´Ü ºÐ¾ß´Â ƯÈ÷ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¾÷ü·Î´Â Thermo Fisher Scientific, Illumina, Eurofins Scientific, Thermo Fisher Scientific, Eurofins Scientific µîÀÌ ÀÖÀ¸¸ç, °¢°¢ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. Thermo Fisher ScientificÀº ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ», Illumina´Â ½ÃÄö½Ì ¿ª·®À» È®´ëÇÏ´Â µî ÀÌµé ±â¾÷ÀÇ Çõ½Å¿¡ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù.

FDA °¡À̵å¶óÀΰú ±¹Á¦ Ç¥ÁØÀ» Æ÷ÇÔÇÑ ±ÔÁ¦ÀÇ ¿µÇâÀº ƯÈ÷ ½ÂÀÎ ÀýÂ÷ ¹× ǰÁú º¸Áõ°ú °ü·ÃÇÏ¿© ½ÃÀåÀÇ ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ¿¬±¸°³¹ß(R&D)°ú ±â¼ú ¹ßÀü¿¡ ´ëÇÑ ÅõÀÚ´Â ¸Å¿ì Áß¿äÇϸç, 2033³â±îÁö R&D ºñ¿ëÀÌ 10% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¾î ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ½Ì¾î ½ÃÄö½Ì ½ÃÀåÀÇ Àü¹ÝÀûÀÎ Àü¸ÁÀº ¿©ÀüÈ÷ ¾çÈ£Çϸç, Áø´Ü ¹× ¿¬±¸¿ëÀ¸·Î Å« ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ±ÔÁ¦ À庮°ú Â÷¼¼´ë ½ÃÄö½Ì ±â¼ú°úÀÇ °æÀïÀº ½ÃÀå ÁøÃâ±â¾÷¿¡°Ô ÀáÀçÀûÀÎ Àå¾Ö¹°ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¥ÀÌÅÍ ºÐ¼®¿¡ AI¿Í °°Àº ÷´Ü ±â¼úÀÇ ÅëÇÕÀº »õ·Î¿î ¼ºÀå °æ·Î¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹ÌÀÇ ½Ì°Å ½ÃÄö½Ì ½ÃÀåÀº źźÇÑ ¿¬±¸ ÀÎÇÁ¶ó¿Í À¯ÀüüÇп¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ¿¡ ÈûÀÔ¾î ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹Àº ÷´Ü ±â¼ú°ú ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °­ÇÑ ÁýÁß·ÂÀ» Ȱ¿ëÇÏ¿© ÀÌ·¯ÇÑ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ij³ª´Ù´Â À¯ÀüÀÚ ¿¬±¸¿Í »ý¸í°øÇп¡ ´ëÇÑ ¸·´ëÇÑ ±â¿©·Î À̸¦ º¸¿ÏÇϰí ÀÖ½À´Ï´Ù.

À¯·´Àº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º¸¦ ÇʵηΠÇÑ À¯·´ÀÌ ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. ÀÌµé ±¹°¡´Â Á¤ºÎ ±¸»ó°ú ÀçÁ¤Àû Áö¿øÀ» ¹ÙÅÁÀ¸·Î ¿¬±¸°³¹ß¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ÇコÄɾî Çõ½Å°ú Á¤¹ÐÀÇ·á¿¡ ÁßÁ¡À» µÎ°í ÀÖÀ¸¸ç, ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº À¯ÀüüÇп¡ ´ëÇÑ ¿¬±¸ Ȱµ¿°ú Á¤ºÎ ÅõÀÚ Áõ°¡¿¡ ÈûÀÔ¾î ±Þ¼ºÀåÇÏ´Â ½ÃÀåÀÔ´Ï´Ù. Áß±¹°ú Àεµ´Â ÇコÄɾî ÀÎÇÁ¶óÀÇ ¼ºÀå°ú À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¸Å¿ì Áß¿äÇÑ ½ÃÀåÀÔ´Ï´Ù. ÀÌ Áö¿ªÀÇ »ý¸í°øÇÐ ºÎ¹®ÀÇ ¼ºÀåµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¶óƾ¾Æ¸Þ¸®Ä«´Â ºê¶óÁú°ú ¸ß½ÃÄÚ¸¦ ÇʵηΠÀ¯¸ÁÇÑ ÀáÀç·ÂÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌµé ±¹°¡´Â ÀÇ·á ¼º°ú¸¦ °³¼±Çϱâ À§ÇØ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿Í À¯ÀüüÇп¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÌ ÀÇ·á ½Ã½ºÅÛ Çö´ëÈ­¿¡ ÁýÁßÇϰí ÀÖ´Ù´Â Á¡ÀÌ À̸¦ ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«´Â ½ÅÈï ½ÃÀåÀ¸·Î ÇコÄɾî ÀÎÇÁ¶ó¿Í ¿¬±¸¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ³²¾ÆÇÁ¸®Ä«°øÈ­±¹°ú ¾Æ¶ø¿¡¹Ì¸®Æ®´Â À¯Àüü ¿¬±¸ ÃßÁø¿¡ ÁÖ·ÂÇϰí ÀÖ´Â ÁÖ¸ñÇÒ ¸¸ÇÑ ±â¿©±¹ÀÔ´Ï´Ù. ÀÌ Áö¿ªÀÇ ÇコÄÉ¾î ¼­ºñ½º °³¼± ³ë·ÂÀº ½ÃÀå È®´ë¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå »ý¾î ½ÃÄö½º ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå¿¡ °üÇÑ ÁÖ¿ä ÀλçÀÌÆ®

Á¦4Àå »ý¾î ½ÃÄö½º ½ÃÀå Àü¸Á

Á¦5Àå »ý¾î ½ÃÄö½º ½ÃÀå Àü·«

Á¦6Àå »ý¾î ½ÃÄö½º ½ÃÀå ±Ô¸ð

Á¦7Àå »ý¾î ½ÃÄö½º ½ÃÀå : À¯Çüº°

Á¦8Àå »ý¾î ½ÃÄö½º ½ÃÀå : Á¦Ç°º°

Á¦9Àå »ý¾î ½ÃÄö½º ½ÃÀå : ¼­ºñ½ºº°

Á¦10Àå »ý¾î ½ÃÄö½º ½ÃÀå : ±â¼úº°

Á¦11Àå »ý¾î ½ÃÄö½º ½ÃÀå : ¿ëµµº°

Á¦12Àå »ý¾î ½ÃÄö½º ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦13Àå »ý¾î ½ÃÄö½º ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

Á¦14Àå »ý¾î ½ÃÄö½º ½ÃÀå : ´Ü°èº°

Á¦15Àå »ý¾î ½ÃÄö½º ½ÃÀå : Áö¿ªº°

Á¦16Àå °æÀï ±¸µµ

Á¦17Àå ±â¾÷ °³¿ä

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global Sanger sequencing market is expected to expand from $3.5 billion in 2023 to $5.9 billion by 2033, reflecting a CAGR of 5.2%.

The Sanger Sequencing Market encompasses the industry dedicated to the development, production, and distribution of Sanger sequencing technologies. This market includes reagents, instruments, and services used in DNA sequencing for applications in genomics, diagnostics, and research. It supports advancements in personalized medicine, genetic testing, and biotechnology, with a focus on high accuracy and reliability in DNA analysis, catering to academic, clinical, and pharmaceutical sectors.

The Sanger Sequencing Market is witnessing robust growth, driven by advancements in genomics and personalized medicine. The consumables segment, particularly reagents and kits, dominates the market, owing to their recurrent demand in sequencing processes. Sequencing services emerge as the second-highest performing sub-segment, propelled by the increasing outsourcing of sequencing projects by research institutions and pharmaceutical companies. Regionally, North America leads the market, attributed to its established healthcare infrastructure and significant investments in research and development. Europe follows as the second most lucrative region, benefiting from supportive governmental policies and a strong emphasis on precision medicine. Within countries, the United States stands out as the top performer, driven by technological innovations and a high concentration of key market players. Germany is the second-highest performing country, supported by its robust biotechnology sector and collaborative research initiatives. These dynamics underscore the market's potential for continued expansion and innovation.

In 2023, the Sanger Sequencing Market was estimated at 300 million sequencing runs, with projections to reach 500 million runs by 2033. The diagnostics segment currently holds the largest market share at 45%, followed by research applications at 35%, and agriculture at 20%. The diagnostics segment is particularly driven by the increasing focus on personalized medicine and the growing prevalence of genetic disorders. Leading players in the Sanger Sequencing Market include Thermo Fisher Scientific, Illumina, and Eurofins Scientific, each commanding significant market shares. The competitive landscape is influenced by these companies' innovations, with Thermo Fisher Scientific emphasizing cost-effective solutions and Illumina expanding its sequencing capabilities.

Regulatory influences, including FDA guidelines and international standards, play a crucial role in shaping market dynamics, particularly concerning approval processes and quality assurance. As the market evolves, investment in research and development (R&D) and technological advancements will be pivotal. The overall outlook for the Sanger Sequencing Market remains positive, with significant opportunities emerging in diagnostics and research applications. However, challenges such as regulatory hurdles and competition from next-generation sequencing technologies continue to pose potential obstacles for market players. The integration of advanced technologies such as AI in data analysis is also expected to create new growth avenues.

The North American Sanger Sequencing Market is a leader, driven by robust research infrastructure and substantial investment in genomics. The United States spearheads this growth, leveraging advanced technology and a strong focus on personalized medicine. Canada complements this with significant contributions in genetic research and biotechnology.

Europe follows closely, with Germany, the United Kingdom, and France at the forefront. These countries emphasize research and development, supported by government initiatives and funding. The region's focus on healthcare innovation and precision medicine further enhances its market position.

Asia Pacific represents a burgeoning market, propelled by increased research activities and government investments in genomics. China and India are pivotal players, with growing healthcare infrastructure and rising demand for genetic testing. The region's expanding biotechnology sector also contributes to market growth.

Latin America shows promising potential, with Brazil and Mexico leading the charge. These countries are investing in biotechnology and genomics to improve healthcare outcomes. The region's focus on modernizing healthcare systems is a driving factor.

The Middle East and Africa are emerging markets, with investments in healthcare infrastructure and research. South Africa and the UAE are notable contributors, focusing on advancing genomic research. The region's efforts to improve healthcare services support market expansion.

Key Companies

Eurofins Genomics, Gen Script Biotech, LGC Biosearch Technologies, Takara Bio, Microsynth, Macrogen, Nimagen, Source Bio Science, Quintara Biosciences, Base Clear, Bio Basic, Genewiz, DNA Sequencing Services, Star SEQ, Seqomics, Sol Gent, Scigenom Labs, Ce Ga T, IIT Biotech, Biofidal

Sources

U.S. National Institutes of Health, European Molecular Biology Laboratory, National Center for Biotechnology Information, Wellcome Sanger Institute, Genome Canada, European Bioinformatics Institute, Human Genome Organisation, International Society for Computational Biology, American Society of Human Genetics, European Society of Human Genetics, Cold Spring Harbor Laboratory, International Conference on Genomics and Molecular Biology, American Association for Cancer Research Annual Meeting, Advances in Genome Biology and Technology Conference, European Human Genetics Conference, National Human Genome Research Institute, World Health Organization - Genomics and Health, Global Alliance for Genomics and Health, International Congress of Human Genetics, International Conference on Genomics.

Research Scope

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Sanger Sequencing Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Sanger Sequencing Market Outlook

5: Sanger Sequencing Market Strategy

6: Sanger Sequencing Market Size

7: Sanger Sequencing Market, by Type

8: Sanger Sequencing Market, by Product

9: Sanger Sequencing Market, by Services

10: Sanger Sequencing Market, by Technology

11: Sanger Sequencing Market, by Application

12: Sanger Sequencing Market, by End User

13: Sanger Sequencing Market, by Component

14: Sanger Sequencing Market, by Stage

15: Sanger Sequencing Market, by Region

16: Competitive Landscape

17: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â